-
Mashup Score: 0
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 2
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/ZZiTZHEwxg
-
-
Mashup Score: 1
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for adv. #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. @AttardLab @ucl joins @ashleyrossmdphd @NM_Urology on UroToday > https://t.co/lp4x0TKZzZ https://t.co/XzhdOPGUid
-
-
Mashup Score: 0Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
@JNCI_Now #CancerSpectrum: @MRCCTU @Prof_Nick_James @mattsydes & team report long-term #STAMPEDE findings: 1️⃣#Docetaxel improves FFS & PFS in non-metastatic #ProstateCancer 2️⃣No excess late toxicity 3️⃣No evidence of long-term outcomes benefits Read more https://t.co/G3y979QnHG https://t.co/668xopMSda
-
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmoeXo @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/ghEBYX7ozl
-
-
Mashup Score: 2
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Insights from the #STAMPEDE trial platform. @marina_parry & Gerhardt Attard, MD, PhD, FRCP @ucl join @CaPsurvivorship @DanaFarber to discuss two key studies from the STAMPEDE trial platform. #WatchNow on UroToday > https://t.co/P9edl74j7c @AttardLab @Decipher_VCYT https://t.co/Gk3VeNacM0
-
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/2eaoOy799O
-
-
Mashup Score: 0How could the STAMPEDE trial shape prostate cancer care? - 2 year(s) ago
In this video interview, filmed at the ESMO 2022 Congress (9–13 September, Paris, France), we speak with Marc Stapley – CEO of Veracyte (CA, USA) and Elai Davicioni Ph.D. – Urology Medical Director of Veracyte about exciting developments in genomic tests. We also explore the STAMPEDE trial, which aims to provide evidence as to what […]
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What are the potential clinical implications of the #STAMPEDE trial for #prostatecancer patients? Our latest video interview explores the trial as well as advancements in genomic tests >>> https://t.co/OvUxK1QqWm @Veracayte
-
-
Mashup Score: 2
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmoeXo @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/XzwViqOTHp
-
-
Mashup Score: 0
ESMO 2022 Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes, abiraterone acetate and prednisolone, standard-of-care androgen-deprivation therapy, metastatic prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
New data presented at #ESMO22 show @Veracyte #Decipher #Prostate genomic classifier may help inform personalized treatment decisions in men with advanced #ProstateCancer. #ReadNow details on UroToday > https://t.co/NfQcAzQsGc @AttardLab @Decipher_VCYT #STAMPEDE https://t.co/gVB1gaUiLy
-
Insights from the #STAMPEDE trial platform. @marina_parry & Gerhardt Attard, MD, PhD, FRCP @ucl join @CaPsurvivorship @DanaFarber to discuss two key studies from the STAMPEDE trial platform. #WatchNow on UroToday > https://t.co/P9edl73LhE @AttardLab @Decipher_VCYT https://t.co/I59Bwb1NJp